Truist Financial Reiterates “Buy” Rating for Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “buy” rating reissued by investment analysts at Truist Financial in a note issued to investors on Tuesday, Benzinga reports. They presently have a $1,200.00 price objective on the biopharmaceutical company’s stock. Truist Financial’s price target would indicate a potential upside of 16.37% from the company’s current price.

A number of other research analysts also recently issued reports on REGN. Barclays lifted their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Wells Fargo & Company reissued an “overweight” rating and issued a $1,200.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Monday. Leerink Partners reaffirmed a “market perform” rating and issued a $1,077.00 target price (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday. Morgan Stanley cut their price target on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Finally, Piper Sandler raised their price objective on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the company an “overweight” rating in a report on Friday, August 23rd. One analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $1,118.62.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $1,031.15 on Tuesday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. Regeneron Pharmaceuticals has a 52-week low of $769.19 and a 52-week high of $1,211.20. The business has a 50 day simple moving average of $1,130.96 and a 200 day simple moving average of $1,034.01. The stock has a market cap of $113.62 billion, a price-to-earnings ratio of 30.46, a PEG ratio of 3.72 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. The business had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm’s quarterly revenue was up 12.3% on a year-over-year basis. During the same period last year, the business posted $8.79 earnings per share. Analysts anticipate that Regeneron Pharmaceuticals will post 37.8 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,137 shares of the stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the transaction, the executive vice president now directly owns 12,931 shares of the company’s stock, valued at approximately $13,540,179.41. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,137 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the transaction, the executive vice president now owns 12,931 shares in the company, valued at approximately $13,540,179.41. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the completion of the sale, the director now directly owns 17,882 shares of the company’s stock, valued at approximately $18,941,329.68. The disclosure for this sale can be found here. In the last 90 days, insiders sold 9,270 shares of company stock valued at $10,695,833. Company insiders own 7.48% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Brown Lisle Cummings Inc. grew its position in Regeneron Pharmaceuticals by 18.2% during the second quarter. Brown Lisle Cummings Inc. now owns 65 shares of the biopharmaceutical company’s stock worth $68,000 after buying an additional 10 shares in the last quarter. Sachetta LLC grew its holdings in shares of Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares in the last quarter. Team Hewins LLC increased its position in shares of Regeneron Pharmaceuticals by 2.5% in the first quarter. Team Hewins LLC now owns 451 shares of the biopharmaceutical company’s stock worth $434,000 after purchasing an additional 11 shares during the period. Angeles Wealth Management LLC raised its stake in Regeneron Pharmaceuticals by 3.5% in the first quarter. Angeles Wealth Management LLC now owns 325 shares of the biopharmaceutical company’s stock valued at $313,000 after purchasing an additional 11 shares in the last quarter. Finally, TrinityPoint Wealth LLC raised its stake in Regeneron Pharmaceuticals by 4.8% in the fourth quarter. TrinityPoint Wealth LLC now owns 262 shares of the biopharmaceutical company’s stock valued at $230,000 after purchasing an additional 12 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.